Fenfluramine: Clinical Trials

10 trials of Fenfluramine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Terminated 2, Active not recruiting 1, Recruiting 1

Follow Fenfluramine: new trials by email Literature Review of Fenfluramine trials Research Report on Fenfluramine

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
fenfluramine hydrochloride, Placebo - Rett Syndrome
Phase 3RecruitingUCB BIOSCIENCES, Inc.2002026-07-142026-11-17
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
fenfluramine - Dravet Syndrome
Phase 3CompletedUCB BIOSCIENCES, Inc.252024-05-212026-09-17
Fenfluramine for Adult Dravet Patients
Fenfluramine - Dravet Syndrome, Dravet Syndrome, Intractable
Phase 3TerminatedUniversity Health Network, Toronto72023-01-112026-05-05
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure
Phase 3Active not recruitingZogenix, Inc.872022-03-082026-04-29
Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Fenfluramine Hydrochloride - Photosensitive Epilepsy
Phase 3CompletedElizabeth Anne Thiele202019-05-312024-11-06
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome, Lennox Gastaut Syndrome
Phase 3CompletedZogenix, Inc.4122019-04-222026-11-18
A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome
Phase 3TerminatedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.52017-07-122023-11-13
A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.872017-01-272022-11-02
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.3752016-06-082025-07-14
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome, Seizure Disorder
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.2622016-01-152023-09-28

Conditions studied

Epilepsies, Myoclonic (7)  ·  Epilepsy (5)  ·  Seizures (5)  ·  Brain Diseases (4)  ·  CDKL5 deficiency disorder (1)  ·  Epilepsy, Reflex (1)  ·  Epilepsy, Tonic-Clonic (1)  ·  Lennox Gastaut Syndrome (1)  ·  Rett Syndrome (1)  ·  Spasms, Infantile (1)

Sponsors

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (4)  ·  UCB BIOSCIENCES, Inc. (2)  ·  Zogenix, Inc. (2)  ·  Elizabeth Anne Thiele (1)  ·  University Health Network, Toronto (1)

Countries

United States (9)  ·  Germany (7)  ·  United Kingdom (7)  ·  Belgium (6)  ·  Italy (6)  ·  Spain (6)  ·  Canada (5)  ·  France (5)  ·  Japan (4)  ·  Netherlands (4)  ·  Australia (3)  ·  Denmark (3)  ·  Georgia (2)  ·  Israel (2)  ·  Poland (2)

Top investigators

Elizabeth Thiele, M.D., Ph.D. (1)

Results publications

PMID 34768178, PMID 33540241, PMID 31790543, PMID 31862249, PMID 34676542, PMID 36562419, PMID 37543865, PMID 40072476, PMID 42400405

NIH funding

2016 (1), 2023 (1)